Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention relates to a production process for a polymeric micelle charged therein with a water-scarcely soluble drug and a polymeric micelle composition as a medicinal preparation.
• Described in Japanese Patent Application Laid-Open No. 107565/1994 is a method in which a micelle is charged therein with a drug by forming in advance a micelle of a block copolymer in an aqueous medium, adding a drug to this micelle solution and, if necessary, mixing and stirring it under heating or supersonic treatment.
• a method for preparing a micelle therein charged with a drug by dissolving a block copolymer and the drug in a water-miscible polar solvent (for example, dimethylformamide, dimethylsulfoxide and acetonitrile) and then dialyzing the solution against water.
• a water-miscible polar solvent for example, dimethylformamide, dimethylsulfoxide and acetonitrile
• an object of the present invention is to provide a method in which a water-scarcely soluble (or oil-soluble) drug can readily and stably be charged into a polymeric micelle and further to provide a polymeric micelle charged therein with a stable drug which can significantly raise a drug concentration in water or a buffered or isotonic aqueous solution.
• a drug particularly a water-scarcely soluble drug can efficiently be charged into a polymeric micelle by simple steps comprising dissolving a drug, particularly a water-scarcely soluble drug and a fixed block copolymer capable of forming a polymeric micelle in an aqueous medium in a water non-miscible organic solvent, preparing an oil-in-water (O/W) type emulsion from the solution thus obtained and water and then volatilizing the organic solvent.
• O/W oil-in-water
• a production process for a polymeric micelle charged is with a water-scarcely soluble drug, comprising the steps of:
• block copolymers represented by the following Formula (I) or (II) described in Japanese Patent Application Laid-Open No. 335267/1999 can suitably be used. It is indicated that in the method described in the above gazette, aspartate in which x to y in the following Formula (I) or (II) is 7:3 to 1:3 can not necessarily efficiently be used in charging a water-scarcely soluble drug.
• composition comprising a polymeric micelle originating in a block copolymer charged therein with a drug, wherein the drug is a water-scarcely soluble drug;
• the block copolymer is represented by the following Formula (I) or (II):
• R 1 and R 3 each represent a hydrogen atom or a lower alkyl group
• R 2 represents a hydrogen atom, a saturated or unsaturated C 1 to C 29 aliphatic carbonyl group or an arylcarbonyl group
• R 4 represents a hydroxyl group, a saturated or unsaturated C 1 to C 30 aliphatic oxy group or an aryl-lower alkyloxy group
• L 1 represents a linkage group selected from the group consisting of —NH—, 13 O— and —OCO-Z-NH— (wherein Z represents a C 1 to C 4 alkylene group);
• L 2 represents a linkage group selected from —OCO-Z-CO— and —NHCO-Z-CO— (wherein Z represents a C 1 to C 4 alkylene group)
• n represents an integer of 10 to 2500, preferably 100 to 1000
• x and y may be the same or different and represent integers the total of which is 10 to 300, preferably 20 to 100
• a water-scarcely soluble drug which has so far been used in the form of a pharmaceutical preparation for dripping because of difficulty to prepare an aqueous liquid preparation having a high drug concentration can be used in the form of a liquid preparation having a high concentration of an effective ingredient, and it is possible as well to use the water-scarcely soluble drug in the form of an injection preparation which makes it possible to administer a required amount of an effective ingredient for short time.
• the “water-scarcely soluble drug” described in the present invention means such a drug that is not substantially dissolved in an equivalent amount of water under an ambient environment of a room temperature and an atmospheric pressure or is distributed preferentially in a chloroform phase in a solvent system of an equivalent amount of water and chloroform.
• drugs including carcinostatic agents such as adriamycin, paclitaxel, docetaxel, methotrexate, vincristine, topotecan and derivatives thereof, macrolide base antibiotics such as ilotycin, erythromycin and clarislomycin, antifungal agents such amphotericin B, itoraconasol, nystatin and miconasol, steroidal antiinflammatory agents such as dexamethasone and triamcinorone, nonsteroidal antiinflammatory agents such as indometacin and dichlophenac, hormones such as estradiol, testosterone, progesterone, diethylstilbestrol and derivatives thereof, prostaglandin, prostacyclin and other drugs for a central nervous system, drugs for a cardiovascular system and drugs for a digestive system.
• carcinostatic agents such as adriamycin, paclitaxel, docetaxel, methotrexate, vincristine, topotecan and derivatives thereof
• the method of the present invention is preferably applied to drugs having a solubility of 5 ⁇ g/ml or less in water at a room temperature.
• drugs having a solubility of 5 ⁇ g/ml or less in water at a room temperature paclitaxel, docetaxel, camptothecin, topotecan and derivatives thereof can be given as such preferred drugs.
• the “block copolymer having a hydrophilic segment and a hydrophobic segment” described in the present invention means a copolymer which can be present in an aqueous medium in the form of a core (mainly comprising hydrophobic segments)-shell (mainly comprising hydrophilic segments) type polymeric micelle and which meets the objects of the present invention.
• Meeting the objects of the present invention means that a polymeric micelle into which a drug is charged (introduced) can be formed at least by a method described later, and the term that a drug is charged means a state in which the drug is sealed principally in a core part (or area) of a polymeric micelle.
• the “hydrophilic segment” constituting such block copolymer shall not be restricted and includes segments originating in poly(ethylene oxide), poly(malic acid), poly(saccharide), poly(acrylic acid), poly(vinyl alcohol) and poly(vinylpyrrolidone).
• the “hydrophobic segment” shall not be restricted and includes segments originating in poly( ⁇ -benzyl aspartate), poly( ⁇ -benzyl glutamate), poly( ⁇ -alkyl aspartate), poly(lactide), poly( ⁇ -caprolactone), poly( ⁇ -valerolactone), poly( ⁇ -butyrolactone), poly( ⁇ -amino acid) and two or more kinds thereof.
• block copolymers containing such segments can be used as they are or after modified.
• block copolymers described in Japanese Patent Application Laid-Open No. 335267/1999 such block copolymers as specified by Formula (I) or (II) are particularly preferred. According to Japanese Patent Application Laid-Open No. 335267/1999, it is indicated that when a carboxyl group unit
• the block copolymers having a form represented by Formula (I) or (II) described above in which an aspartate unit is partially hydrolyzed among the block copolymers can more suitably be used in order to stabilize the polymeric micelle charged therein with the drug in an aqueous medium.
• the “short chain alkyl group” represented by R 1 and R 3 can be a linear or branched chain having 1 to 6 carbon atoms and includes methyl, ethyl, isopropyl, n-butyl and isoamyl.
• the “saturated or unsaturated C 1 to C 29 aliphatic carbonyl group or arylcarbonyl group” represented by R 2 can be acetyl, propionyl, isopropionyl, decanoyl, dodecanoyl (lauroyl), tetradecanoyl (myristoyl), hexadecanoyl (palmitoyl), octadecanoyl, 9,12-octadecadienoyl (linoloyl), icosanoyl (arachidonoyl) and benzoyl.
• the “saturated or unsaturated C 1 to C 30 aliphatic oxy group or aryl-lower alkyloxy group” represented by R 4 can be methoxy, ethoxy, octyloxy, docosyloxy and benzyloxy.
• L 1 and L 2 are linkage groups which can freely be changed depending on the production process of the block copolymers represented by Formulas (I) and (II).
• the polymer in which L 1 is —NH—, —O— or —OCO-Z-NH— can be obtained when an ⁇ -amino acid chain is extended via an amino group shown below by a carbon dioxide-eliminating polymerization method (so-called NCA method) in which after forming a polyoxyethylene segment by anion-living polymerization, a hydroxyl group at a ⁇ -terminal is converted to an amino group or a —OCO-Z-NH 2 group (Z is a C 1 to C 4 alkylene group) and then an N-carboxylic acid anhydride of ⁇ -benzyl aspartate is used.
• NCA method carbon dioxide-eliminating polymerization method
• the polymer in which L 1 is —O— includes those obtained by forming a polyoxyethylene segment by anion-living polymerization and extending a polyamino acid segment at a ⁇ -terminal thereof by the NCA method or condensing polyoxyethylene with poly- ⁇ -benzyl aspartate which is separately produced by the NCA method.
• the block polymer represented by Formula (II) includes usually those which can be provided by separately producing polyoxyethylene and poly- ⁇ -benzyl aspartate and then converting a ⁇ -terminal of polyoxyethylene to a carboxyl group or, if necessary, linking a carboxyl group with an N-terminal amino group of polyamino acid via a C 1 to C 6 alkylenedicarboxylic acid.
• the block copolymer containing a desired extent of the free aspartic acid unit described above can advantageously be produced by subjecting the poly- ⁇ -benzyl aspartate segment (or block) described above to a partial hydrolytic reaction.
• the specific production process of the block copolymer described above is specifically described in Japanese Patent Application Laid-Open No. 335267/1999, and therefore it can be referred to, if necessary.
• the present invention shall further be explained below with reference mainly to an example in which the block copolymer represented by Formula (I) is used, and other various block copolymers shall be able to be used as well by modifying a little.
• the “water non-miscible organic solvent” described in the present invention means a solvent having a concept opposed to dimethylformamide, dimethylsulfoxide and acetonitrile which are substantially freely miscible with water and which are used for forming a polymeric micelle in Japanese Patent Application Laid-Open No. 335267/1999. It shall not be restricted, and specific examples thereof include chloroform, methylene chloride, toluene, xylene, n-hexane or a mixture thereof.
• a solution obtained by dissolving a drug and a block copolymer in a water non-miscible organic solvent can be prepared by separately dissolving the drug and the block copolymer in the solvents and then joining them together or mixing and dissolving the drug and the block copolymer in a single vessel at the same time. If the solution containing a concentrated solute has to be prepared, the solute is dissolved (or homogeneously dispersed) in a large amount of a solvent, and then a fixed amount of the solvent may slowly be distilled off.
• a preferred range of a mixing ratio of the drug used to the block copolymer can be changed depending on the kind of the drug used and a charging rate of the intended drug and therefore is not specified. In general, it is 1:20 to 2:5, preferably 1:10 to 1:3 in terms of a weight ratio of the drug to the block copolymer.
• a step (B) the organic solution thus prepared is mixed with an aqueous medium to prepare an oil-in-water (O/W) type emulsion.
• Water including purified water or ion-exchanged water
• the aqueous medium may further contain a small amount of a water-miscible organic solvent and other inorganic salts (for example, sodium sulfate and the like) as long as they do not exert an adverse effect to formation of the O/W type emulsion.
• the organic solvent and the aqueous medium are mixed in a volume ratio of 1:100, preferably 1:20.
• this mixing means are means conventionally used for preparing various emulsions, a mechanical stirrer, a shaker and a supersonic irradiating equipment.
• An operating temperature of such means shall not be restricted and is set preferably to a range of about ⁇ 5 to about 40° C. considering a temperature stability of the drug and a boiling point of the solvent.
• the O/W type emulsion is formed, and then the mixing operation described above is continued in an open system or the organic solvent is vaporized and removed (or volatilized and removed) under reduced pressure while stirring.
• the organic solvent is vaporized and removed (or volatilized and removed) under reduced pressure while stirring.
• volatilization of the organic solvent goes on, the emulsion is changed to a polymeric micelle solution (or dispersion).
• the polymeric micelle solution may be subjected to filtering treatment of insolubles and deposited matters by means of a filtering membrane as it is or after subjecting to supersonic treatment if there is a possibility that the polymeric micelle is associated or coagulated.
• the filtering membrane used shall not be restricted, and a membrane having a pore diameter of about 1 ⁇ m is preferred.
• sodium chloride contained in a physiological saline solution is removed by dialysis to obtain a micelle medicine.
• the dialysis membrane shall not be restricted by a material and a pore diameter as long as it can efficiently separate the raw material, solvent, drug and polymer used. Usually, a cellulose membrane is used. After dialysis, supersonic treatment may further be carried out to mono-disperse the associated micelles.
• the polymeric micelle according to the present invention is stable in the aqueous medium as described above, and the drug concentration in the liquid preparation can be raised.
• concentration by filtration or freeze-drying can be carried out.
• the method described above makes it possible to control the drug concentration to 10 to 30% by weight based on the total weight of the drug and the copolymer.
• the copolymer represented by Formula (I) capable of being provided is the composition of the aqueous medium in which the polymeric micelle can stably be maintained in a drug concentration of about 3 mg, preferably about 6 mg and particularly preferably about 10 mg per ml of the polymer micelle solution.
• Being capable of stably maintaining the polymeric micelle means that when the above composition is left standing at a room temperature, association between the polymeric micelles and discharge of the drug from the polymeric micelle are not brought about at least for several hours. The above association and discharge of the drug can be confirmed by optical inspection or visual observation.
• the tightly sealed stopper was removed 30 minutes later, and chloroform was distilled off while slowly stirring at a room temperature for a whole day and night, whereby a polymeric micelle aqueous solution charged therein with the drug was obtained.
• the polymeric micelle solution was irradiated with a probe type supersonic apparatus for 15 minutes by applying intermittent oscillation by every second to sufficiently disperse the micelles. Then, the solution was filtered by means of a filter having a pore diameter of 0.45 ⁇ m and further dialyzed to remove sodium chloride. Thereafter, a sodium chloride solution was added to reduce the solution to isotonicity. Further, the solution was pressure-filtered and concentrated by means of an Amicon ultrafilter (UK200 membrane). This provided a polymeric micelle aqueous solution having a paclitaxel concentration of 13.5 mg/ml. This solution had a chloroform content of 5 ppm or less.
• Added thereto was 5 ml of a 5% sodium chloride aqueous solution, and the tube was tightly sealed and vigorously stirred to form an O/W emulsion.
• the tightly sealed stopper was removed 30 minutes later, and chloroform was distilled off while slowly stirring at a room temperature for a whole day and night, whereby four kinds of polymeric micelle aqueous solutions charged therein with the drug were prepared.
• the polymeric micelle solutions were irradiated with a probe type supersonic apparatus for 15 minutes by applying intermittent oscillation by every second to sufficiently disperse the micelles. Then, the solutions were filtered by means of a filter having a pore diameter of 0.45 ⁇ m.
• the paclitaxel concentrations in a stage before concentration were 1.8, 1.9, 1.6 and 1.7 mg/ml respectively.
• the tightly sealed stopper was removed 30 minutes later, and chloroform was distilled off while slowly stirring at a room temperature for a whole day and night, whereby a polymeric micelle aqueous solution charged therein with the drug was prepared.
• the polymeric micelle solution was irradiated with a probe type supersonic apparatus for 15 minutes by applying intermittent oscillation by every second to sufficiently disperse the micelles. Then, the solution was filtered by means of a filter having a pore diameter of 0.45 ⁇ m. Thereafter, a sodium chloride solution was added to reduce the solution to isotonicity.
• the paclitaxel concentration in a stage before concentration was 1.6 mg/ml.
• the tightly sealed stopper was removed 30 minutes later, and chloroform was distilled off while slowly stirring at a room temperature for a whole day and night, whereby a polymeric micelle aqueous solution charged therein with the drug was prepared.
• the polymeric micelle solution was irradiated with a probe type supersonic apparatus for 15 minutes by applying intermittent oscillation by every second to sufficiently disperse the micelles. Then, the solution was filtered by means of a filter having a pore diameter of 0.45 ⁇ m.
• the paclitaxel concentration in a stage before concentration was 1.1 mg/ml.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Dispersion Chemistry (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=18556810

Family Applications (2)

Family Applications After (1)

Country Status (9)

Cited By (22)

Families Citing this family (42)

Family Cites Families (5)

• 2000
  • 2000-02-09 JP JP2000032156A patent/JP3523821B2/ja not_active Expired - Lifetime
• 2001
  • 2001-02-06 KR KR1020010005542A patent/KR100797429B1/ko active IP Right Grant
  • 2001-02-07 DE DE60104340T patent/DE60104340T2/de not_active Expired - Lifetime
  • 2001-02-07 EP EP01102734A patent/EP1127570B1/fr not_active Expired - Lifetime
  • 2001-02-07 AT AT01102734T patent/ATE271380T1/de not_active IP Right Cessation
  • 2001-02-08 US US09/778,901 patent/US20010014354A1/en not_active Abandoned
  • 2001-02-08 CA CA2334615A patent/CA2334615C/fr not_active Expired - Lifetime
  • 2001-02-08 TW TW090102740A patent/TWI235069B/zh not_active IP Right Cessation
  • 2001-02-08 CN CNB011034351A patent/CN1188112C/zh not_active Expired - Fee Related
• 2003
  • 2003-09-22 US US10/666,384 patent/US7223419B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events